ConductScience.org, home

Paper1605902

Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).

Eyres KS and 4 others. Drug Saf, 1992. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Papers, record 1605902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1605902

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).
PubMed
Journal
Drug Saf
PubMed
Year
1992
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
0.78
iCite
Revised in PubMed
2018-11-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Eyres KSK S
2Marshall PP
3McCloskey EE
4Douglas DLD L
5Kanis JAJ A

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Etidronic AcidMajor topic
Fractures, SpontaneousMajor topic
Osteitis DeformansMajor topic
Aged
Aged, 80 and over
Female
Femoral Neck Fractures
Humans
Osteomalacia
Tibial Fractures

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16820112Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone.Metab Bone Dis Relat Res1981https://conductscience.org/library/papers/6820112PubMed
26401608Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP).Clin Orthop Relat Res1983https://conductscience.org/library/papers/6401608PubMed
352045Letter: Disodium ethane-1-hydroxy-1, 1-diphosphonate(E.H.D.P.) in Paget's disease.Lancet1975https://conductscience.org/library/papers/52045PubMed
44201876Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).N Engl J Med1973https://conductscience.org/library/papers/4201876PubMed
54206518Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.Q J Med1973https://conductscience.org/library/papers/4206518PubMed
686042Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).Lancet1979https://conductscience.org/library/papers/86042PubMed
76101833Calcitonin or diphosphonates for osteolytic Paget's disease?Lancet1980https://conductscience.org/library/papers/6101833PubMed
84213513Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate.JAMA1974https://conductscience.org/library/papers/4213513PubMed
92863616Etidronate and the risk of fractures.Lancet1985https://conductscience.org/library/papers/2863616PubMed
10401827Diphosphonate therapy of paget's disease of bone.J Clin Endocrinol Metab1977https://conductscience.org/library/papers/401827PubMed
116220190Paget's disease of bone: diagnosis and management.Metab Bone Dis Relat Res1981https://conductscience.org/library/papers/6220190PubMed
123085989Absorption of oral diphosphonate in normal subjects.Clin Endocrinol (Oxf)1986https://conductscience.org/library/papers/3085989PubMed
13412450Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results.Ann Intern Med1977https://conductscience.org/library/papers/412450PubMed
14410576Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).Clin Orthop Relat Res1977https://conductscience.org/library/papers/410576PubMed
156143140Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease.Lancet1984https://conductscience.org/library/papers/6143140PubMed

Download CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
17503893Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.Drugs Aging2007https://conductscience.org/library/papers/17503893PubMed
12184516What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.Dig Dis Sci2002https://conductscience.org/library/papers/12184516PubMed
11595119The role of bisphosphonates as adjuvant therapy for breast cancer.Curr Oncol Rep2001https://conductscience.org/library/papers/11595119PubMed
7858370Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs Aging1994https://conductscience.org/library/papers/7858370PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1605902

GET https://conductscience.org/api/papers/v1/1605902/authors